Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy

Article Information

vol. 44 no. 3 1271-1279

DOI

PMID

Published By

Print ISSN

0250-7005

Online ISSN

1791-7530

History

TETSUYA SHINDO¹ ⇑,
KOHEI HASHIMOTO¹,
ATSUSHI TAKAHASHI²,
SHINTARO MIYAMOTO³,
YASUHARU KUNISHIMA⁴,
SHUNSUKE SATO⁵,
FUMIMASA FUKUTA⁶,
YOSHIKI HIYAMA⁷,
AKIO TAKAYANAGI⁸,
RYUICHI KATO⁹,
ATSUSHI WANIFUCHI¹⁰,
YOHEI UEKI¹¹,
MANABU OKADA¹²,
HIDEKI ADACHI¹³,
KO KOBAYASHI¹,
TOSHIAKI TANAKA¹ and
NAOYA MASUMORI on behalf of the Sapporo Medical University Urologic Oncology Consortium¹

¹Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan;
²Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan;
³Department of Urology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan;
⁴Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan;
⁵Department of Urology, Oji General Hospital, Tomakomai, Japan;
⁶Department of Urology, Steel Memorial Muroran Hospital, Muroran, Japan;
⁷Department of Urology, NTT Medical Center Sapporo, Sapporo, Japan;
⁸Department of Urology, Japan Community Healthcare Organization Hokkaido Hospital, Sapporo, Japan;
⁹Department of Urology, Muroran City General Hospital, Muroran, Japan;
¹⁰Department of Urology, Japanese Red Cross Kushiro Hospital, Kushiro, Japan;
¹¹Department of Urology, Takikawa Municipal Hospital, Takikawa, Japan;
¹²Department of Urology, Obihiro Kyokai Hospital, Obihiro, Japan;
¹³Department of Urology, Saiseikai Otaru Hospital, Otaru, Japan

Correspondence to: Tetsuya Shindo (ORCID: 0000-0002-4990-8330), MD, Ph.D., Department of Urology, Sapporo Medical University School of Medicine, S1W16, Chuo-ku, Sapporo 060-8543, Japan. Tel: +81 116112111 ext. 34720, Fax: +81 116122709, e-mail: shindo1013{at}yahoo.co.jp